PREVIOUS
✖
TB drug – Bedaquiline
March 28 , 2023
480 days
350
0
- Pharma major Johnson and Johnson made application to extend its patent on anti-Tuberculosis drug Bedaquiline that expires in July this year.
- The Indian Patent Office rejected this application.
- The patent would have extended J&J’s monopoly on the drug in India till 2027.
- But with this rejection, generic manufacturers can now make their own versions at an affordable price from this year.
Leave a Reply
Your Comment is awaiting moderation.